Biohaven files license and assignment agreements for SK Biopharmaceuticals Kv7 deal
New SEC filing details royalty terms, termination rights, and a separate $245 million Knopp Biosciences obligation tied to the opakalim licensing deal.
SEC filing
Latest
4 stories
Wednesday, August 26
Monday, August 10
Biohaven advances degrader and epilepsy pipelines, reports Q2 2026 results
Biohaven started a pivotal Phase 3 trial for BHV-1300 in Graves' disease and reported new biomarker data across its degrader and epilepsy programs, with cash of $270.5 million as of June 30, 2026.
SEC filing
Friday, August 7
Biohaven adds John Yetimoglu to board of directors
The appointment, effective August 6, 2026, was disclosed in an 8-K filed after an August 3 board action.
SEC filing
Thursday, July 9
Biohaven announces leadership changes as Car retires, Pirman promoted
Biohaven's chief scientific officer moves to a new part-time innovation role while David Pirman takes over discovery operations, effective July 13, 2026.
SEC filing